Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 29;13(4):930-935.
doi: 10.21037/tlcr-24-117. Epub 2024 Apr 15.

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

Matthew Dankner  1   2   3 , Jennifer Maxwell  2   4 , April A N Rose  1   2   4
Affiliations
Editorial

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

Matthew Dankner et al. Transl Lung Cancer Res. .
No abstract available

Keywords: BRAF; binimetinib; encorafenib; mitogen activated protein kinase (MAPK).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-117/coif). A.A.N.R. reports a Canadian Cancer Society Challenge Grant (#707457), honoraria from Advanced Accelerator Applications for lectures, and honoraria from EMD Serono for participating in an advisory board, which is unrelated to the topics discussed in this manuscript. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Clinical, pathological, and genetic features in patients with BRAF V600 and BRAF non-V600 mutated non-small cell lung cancer. Figure was created with Canva online software. NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NOS, not otherwise specified; Mb, mega base; WT, wild-type.
See this image and copyright information in PMC

Comment on

References

    1. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:339-57. 10.1016/j.annonc.2022.12.009 - DOI - PubMed
    1. Riely GJ, Smit EF, Ahn MJ, et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2023;41:3700-11. Erratum in: J Clin Oncol 2024;42:245. 10.1200/JCO.23.00774 - DOI - PubMed
    1. Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 2018;37:3183-99. 10.1038/s41388-018-0171-x - DOI - PubMed
    1. Guaitoli G, Zullo L, Tiseo M, et al. Non-small-cell lung cancer: how to manage BRAF-mutated disease. Drugs Context 2023;12:2022-11-3. 10.7573/dic.2022-11-3 - DOI - PMC - PubMed
    1. Kazandjian S, Rousselle E, Dankner M, et al. The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers. Cancers (Basel) 2024;16:445. 10.3390/cancers16020445 - DOI - PMC - PubMed